Drugs / 5-MTHF
5-MTHF
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01331655 | Apr 2013 → Nov 2014 | — | Bayer | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00626223 | Jan 1998 → Jul 2001 | hyperhomocysteinemia | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-MTHF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00626223 ↗ |
| Known as | 5-methyltetrahydrofolate | “5-MTHF (5-methyltetrahydrofolate)” NCT00626223 ↗ |
| Known as | L-5-MTHF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01331655 ↗ |
| Known as | Prefolic | “patients treated with intravenous 5-MTHF (Prefolic®, Knoll, Milan, Italy) 50 mg at the end of each hemodialysis session” NCT00626223 ↗ |
| Route | Intravenous | “50 mg intravenous at the end of each hemodialysis session” NCT00626223 ↗ |